Lack of Evidence for Deterioration in Endothelial Function Following Ticagrelor Treatment Cessation.
Abstract BACKGROUND: Ticagrelor may exert pleiotropic actions, beyond platelet inhibition, which are possibly adenosine-mediated. It has been suggested that in patients with coronary artery disease (CAD) ticagrelor may influence endothelial function. OBJECTIVE: We aimed to assess the possibility of endothelial function deterioration following ticagrelor treatment cessation. METHODS: This was a prospective, observational study, in stable CAD patients with prior percutaneous coronary intervention (PCI) for acute coronary syndrome manifested 1 year earlier, under ticagrelor maintenance dose (90 mg bid) and ...
Source: Current Vascular Pharmacology - June 24, 2016 Category: Drugs & Pharmacology Authors: Xanthopoulou I, Vogiatzi C, Bampouri T, Chasapi A, Bei I, Davlouros P, Hahalis G, Alexopoulos D Tags: Curr Vasc Pharmacol Source Type: research

Virulence Potential of Staphylococcus Aureus Strains Isolated From Diabetic Foot Ulcers Among Patients From Southern Poland.
wska-Mach J Abstract The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) was investigated among infected diabetic foot ulcers in hospitalized and non-hospitalized patients in southern Poland to assess the virulence patterns and antimicrobial resistance among these strains. MRSA was detected in 10.3% of all studied isolates, from the hospitalized patients only. The rest of the isolates was methicillin susceptible. The minimal inhibitory concentration that inhibits 50% of bacterial isolates (MIC50) for vancomycin was 1.0 mg/mL. The mupA gene was detected in six (8.8%) isolates, in one MRSA strain an...
Source: Current Vascular Pharmacology - June 24, 2016 Category: Drugs & Pharmacology Authors: Pobiega M, Myjak I, Pomorska-Wesolowska M, Romaniszyn D, Ziólkowski G, Chmielarczyk A, Maciag J, Szczyptaf A, Wójkowska-Mach J Tags: Curr Vasc Pharmacol Source Type: research

The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease.
Abstract The estimation of risk for atherosclerotic cardiovascular (CV) events based only on the presence of classical risk factors is often insufficient. Therefore, efforts have been made to find markers that indicate the presence of preclinical or clinical disease. Inflammation mediates all stages of the disease, from initiation to the thrombotic complications of atherosclerosis. Raised levels of several circulating markers, particularly inflammatory mediators, have been reported in subjects with atherosclerosis. Increased risk for CV events is associated with increased levels of cytokines, cell-adhesion molecul...
Source: Current Vascular Pharmacology - June 24, 2016 Category: Drugs & Pharmacology Authors: Poredos P, Jezovnik MK Tags: Curr Vasc Pharmacol Source Type: research

The Effect of Nicotine and Tobacco on Aortic Matrix Metalloproteinases in the Production of Aortic Aneurysm.
CONCLUSION: Nicotine and tobacco constituents translate the exposure to cigarette smoke into increased MMP expression through various molecular mechanisms whose interruption can form the basis for pharmacologic management of AAs. PMID: 27363715 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - June 24, 2016 Category: Drugs & Pharmacology Authors: Rabkin SW Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?
PMID: 27173023 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 13, 2016 Category: Drugs & Pharmacology Authors: Athyros VG, Katsiki N, Mikhailidis DP Tags: Curr Vasc Pharmacol Source Type: research

Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?
PMID: 27173024 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 13, 2016 Category: Drugs & Pharmacology Authors: Sahebkar A, Maffioli P, Banach M, Derosa G Tags: Curr Vasc Pharmacol Source Type: research

Commentary: Perivascular Fat and Improved Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Surgery.
PMID: 27173025 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 13, 2016 Category: Drugs & Pharmacology Authors: Fernandez-Alfonso MS, Souza DS, Dreifaldt M, Dashwood MR Tags: Curr Vasc Pharmacol Source Type: research

Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
Abstract OBJECTIVE: Chronic heart failure (CHF) remains a major health problem, with high levels of morbidity and mortality and a low health-related quality of life (HRQoL). We assessed the impact on HRQoL of adding the If channel blocker, ivabradine, to a standard treatment regimen of patients with ischaemic CHF (I-CHF) and heart rate (HR) ≥70 beats/min (bpm). METHODS: A randomized prospective study of 100 consecutive patients presenting with stable I-CHF, left ventricular ejection fraction (LVEF)
Source: Current Vascular Pharmacology - May 5, 2016 Category: Drugs & Pharmacology Authors: Sallam M, Al-Saadi T, Alshekaili L, Al-Zakwani I Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Your VISION Will Become Clear Only When You Look Into Your Heart.
PMID: 27087110 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 18, 2016 Category: Drugs & Pharmacology Authors: Paraskevas KI, Mikhailidis DP, Stansby GP Tags: Curr Vasc Pharmacol Source Type: research

Plasma VEGF and IL-8 levels in patients with mixed dyslipidaemia. Effect of rosuvastatin monotherapy or its combination at a lower dose with omega-3 fatty acids: A pilot study.
Abstract OBJECTIVES: Hypercholesterolaemia is associated with increased plasma levels of vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8). We studied the effect of rosuvastatin monotherapy or its combination at a lower dose with omega-3 polyunsaturated fatty acids (ω-3 PUFAs) in the VEGF and IL-8 plasma levels in patients with mixed dyslipidaemia. METHODS: Fifty patients with mixed dyslipidaemia were recruited. Fifty-five normolipidaemic, apparently healthy, age- and sex- matched subjects acted as controls. Patients were randomized to 40 mg/day rosuvastatin (R group, n=26) or 10 mg/day...
Source: Current Vascular Pharmacology - April 4, 2016 Category: Drugs & Pharmacology Authors: Chantzichristos VG, Agouridis AP, Moutzouri E, Stellos K, Elisaf MS, Tselepis AD Tags: Curr Vasc Pharmacol Source Type: research

Increased serum HMGB-1, ICAM-1 and Metalloproteinase-9 levels in Buerger's patients.
This study was carried out to investigate HMGB-1 (high mobility group box-1), MMP (matrix metalloproteinase)-2, MMP-9, MMP-11 and ICAM (intercellular adhesion molecule)-1 circulating levels in subjects with Buerger's disease. METHODS: Between January 2010 and December 2012 eight patients underwent surgical revascularization of the lower limbs and a specimen of the affected arterial wall was obtained for histological confirmation of Buerger's disease. The same day a blood sample was collected for measuring HMGB-1, MMP-3, MMP-9 and ICAM-1 by western blot analysis. Controls (n=7) were healthy non-smokers. RESULTS: T...
Source: Current Vascular Pharmacology - March 2, 2016 Category: Drugs & Pharmacology Authors: De Caridi G, Bitto A, Massara M, Pallio G, Pizzino G, Serra R, Altavilla D, Squadrito F, Spinelli F Tags: Curr Vasc Pharmacol Source Type: research

Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: "and Death Shall Have no Dominion"?
Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: "and Death Shall Have no Dominion"? Curr Vasc Pharmacol. 2016 Feb 29; Authors: Papanas N, Tsioufis C, Maltezos E PMID: 26924324 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - February 29, 2016 Category: Drugs & Pharmacology Authors: Papanas N, Tsioufis C, Maltezos E Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Statins and Tissue Plasminogen Activator for Stroke: A Beneficial Combination?
PMID: 26924325 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - February 29, 2016 Category: Drugs & Pharmacology Authors: Siniscalchi A, Sanguigni S, Lochner P, De Sarro G, Malferrari G, Gallelli L Tags: Curr Vasc Pharmacol Source Type: research

Effects of antiplatelet medication on arteriovenous fistula patency after surgical thrombectomyNiki.
Abstract OBJECTIVES: To study the effect of antiplatelet agents on preventing arteriovenous (AV) fistulae thrombosis in hemodialysis (HD) patients after surgical thrombectomy (ST) for acute AV fistulae occlusion. Whether post-operative antiplatelet drugs have similar effects on the patency of AV fistula after surgical thrombectomy in patients with end-stage renal disease who undergo HD has not been investigated. DESIGN, MATERIALS AND METHODS: We employed the Taiwan National Health Insurance Research Database (NHIRD) from 1999 to 2010 to assess the recurrent occlusion requiring ST and longevity of AV fistula a...
Source: Current Vascular Pharmacology - February 28, 2016 Category: Drugs & Pharmacology Authors: Yeh CH, Huang TS, Wang YC, Huang PF, Huang TY, Chen TP, Yin SY, Yu YW Tags: Curr Vasc Pharmacol Source Type: research

Effect of HMG-CoA Reductase Inhibition on Vascular Smooth Muscle Cells Extracellular Matrix production: Role of RhoA.
Abstract Cholesterol-lowering effects apart, statins can improve the endothelial function, stabilize the atherosclerotic plaques, decrease the oxidative stress and inflammation and inhibit the thrombogenic response by means of the inhibition of isoprenoids, which serve as lipid attachments for intracellular signaling molecules. We aimed to evaluate whether the effect of statins on RhoA activity mediate extracellular matrix production, particularly affecting collagen type I, in smooth muscle cells (SMCs). Our results showed that lovastatin decreased collagen expression in primary cultured chicken SMCs as determined...
Source: Current Vascular Pharmacology - February 28, 2016 Category: Drugs & Pharmacology Authors: Palomino-Morales R, Perales S, Torres C, Linares A, Alejandre MJ Tags: Curr Vasc Pharmacol Source Type: research

Utilization of evidence-based secondary prevention medications at the time of discharge in patients with acute coronary syndrome (ACS) in Qatar.
CONCLUSION: Most ACS patients were prescribed antiplatelets, β-blockers and statins, but the use of ACEIs or ARBs was suboptimal. Strategies are needed to enhance ACEI or ARB prescribing, especially for high risk patients who would have the greatest therapeutic benefit from these drugs. PMID: 26916397 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - February 26, 2016 Category: Drugs & Pharmacology Authors: El Hajj MS, Saad A, Suwaidi JA, Al Marridi WF, Elkhalifa DH, Mohamed A, Mahfoud ZR Tags: Curr Vasc Pharmacol Source Type: research

Exploring the management of statin intolerant patients: 2016 and beyond.
Abstract Statins remain the cornerstone of lipid-lowering treatment.They significantly reducing cardiovascular morbidity and mortality in primary and secondary prevention settings. Statin-treated patients may present adverse events (clinical and/or biochemical) that can lead to treatment discontinuation or a reduction in the dose of statins. Statin intolerance may appear at any time during the treatment. In each case, secondary causes should be assessed and treated and lifestyle measures should be implemented. Up to 3 different statins can be tried at a low dose; statin dosing every-other-day or once weekly may be...
Source: Current Vascular Pharmacology - February 26, 2016 Category: Drugs & Pharmacology Authors: Katsiki N, Athyros VG, Karagiannis A Tags: Curr Vasc Pharmacol Source Type: research

Microcirculation Alteration and Biomarker Dilemma in Early Septic Shock Diagnosis and Treatment.
CONCLUSION: It is crucial to improve microvascular perfusion through targeted interventions using patient-centred approach. Moreover, systems biology approach could play a promising role in understanding the immune complexity, characterization of gene expression patterns, and recognition of novel therapeutic targets which could be used as clinical decision making tool in the future. PMID: 26916399 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - February 26, 2016 Category: Drugs & Pharmacology Authors: El-Menyar A, Al Ashry H, Abuzaid A, Asim M Tags: Curr Vasc Pharmacol Source Type: research

Nitric oxide is a central common metabolite in vascular dysfunction associated with diseases of human pregnancy.
Sobrevia L Abstract Preeclampsia (PE), gestational diabetes mellitus (GDM), and maternal supraphysiological hypercholesterolaemia (MSPH) are pregnancy-related conditions that cause metabolic disruptions leading to alterations of the mother, fetus and neonate health. These syndromes result in fetoplacental vascular dysfunction, where nitric oxide (NO) plays a crucial role. PE characterizes by abnormal increase in the placental blood pressure and a negative correlation between NO level and fetal weight, suggesting that increased NO level and oxidative stress could be involved. GDM courses with macrosomia along with...
Source: Current Vascular Pharmacology - February 21, 2016 Category: Drugs & Pharmacology Authors: Leiva A, Fuenzalida B, Barros E, Sobrevia B, Salsoso R, Sáez T, Villalobos R, Silva L, Chiarello I, Toledo F, Gutiérrez J, Sanhueza C, Pardo F, Sobrevia L Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Endothelium: A Target for Therapeutic Intervention.
PMID: 26864444 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - February 14, 2016 Category: Drugs & Pharmacology Authors: Dashwood MR Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs.
Abstract Vascular calcification, both in the coronary and in the peripheral arteries, is associated with increased cardiovascular (CV) risk. However, agents that prevent vascular calcification (e.g. estrogens or calcimimetic agents) might have neutral or detrimental effects on CV events. Moreover, statins and antihypertensive agents do not appear to modify vascular calcification, despite their established benefits on CV disease prevention. On the other hand, recent data suggest that microRNAs play a role in the regulation of vascular calcification. It is therefore possible that modulation of the expression of micr...
Source: Current Vascular Pharmacology - February 14, 2016 Category: Drugs & Pharmacology Authors: Tziomalos K, Athyros VG, Karagiannis A Tags: Curr Vasc Pharmacol Source Type: research

Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients.
Abstract Subclinical hypothyroidism (SH) is characterized by a mildly elevated concentration of thyroid stimulating hormone (TSH) despite free thyroxine (FT4) and triiodothyronine (FT3) levels within the reference range. Numerous studies revealed SH to be an independent risk factor for cardiovascular disease (CVD), including atherosclerosis, congestive heart failure, coronary heart disease, ischemic heart disease and the associated mortality. The relationship between SH and CVD is well documented, but the molecular mechanism underlying this correlation remain unknown. Endothelial dysfunction has been recognized as...
Source: Current Vascular Pharmacology - February 8, 2016 Category: Drugs & Pharmacology Authors: Obradovic M, Gluvic Z, Sudar-Milovanovic E, Panic A, Trebaljevac J, Bajic V, Zarkovic M, Isenovic ER Tags: Curr Vasc Pharmacol Source Type: research

Virgin Olive Oil and Hypertension.
Abstract The incidence of high blood pressure (BP) along with other cardiovascular (CV) risk factors on human health has been studied for many years. These studies have proven a link between unhealthy dietary habits and sedentary lifestyle with the onset of hypertension, which is a hallmark of CV and cerebrovascular diseases. The Mediterranean diet, declared by the UNESCO as an Intangible Cultural Heritage since 2013, is rich in vegetables, legumes, fruits and virgin olive oil. Thanks to its many beneficial effects, including those with regard to lowering BP, the Mediterranean diet may help people from modern coun...
Source: Current Vascular Pharmacology - January 17, 2016 Category: Drugs & Pharmacology Authors: Lopez S, Bermudez B, Montserrat-de la Paz S, Jaramillo S, Abia R, Muriana FJ Tags: Curr Vasc Pharmacol Source Type: research

The problem of atrial fibrillation in patients with chronic kidney disease.
ysz J Abstract Chronic kidney disease (CKD) is associated with the risk of multiple life-threatening complications such as: progression to chronic renal failure and cardiovascular disease including coronary heart disease, heart failure and peripheral arterial disease. Also, atrial fibrillation (AF) is common in this group of patients. Factors contributing to the occurrence of AF in patients undergoing dialysis include: age, presence of coronary heart disease, echocardiographic abnormalities (low ejection fraction, atrial enlargement, valvular calcification, left ventricular hypertrophy), heart failure, chronic obs...
Source: Current Vascular Pharmacology - January 15, 2016 Category: Drugs & Pharmacology Authors: Franczyk B, Gluba-Brzózka A, Ciałkowska-Rysz A, Banach M, Rysz J Tags: Curr Vasc Pharmacol Source Type: research

Evaluation of endothelial (dys)function, left ventricular structure and function in patients with chronic kidney disease.
ysz J Abstract BACKGROUND: Endothelial dysfunction is involved in the pathogenesis of atherosclerosis and cardiovascular complications in chronic kidney disease (CKD). Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase (eNOS), is considered as a marker of endothelial dysfunction. The aim of this study was to evaluate serum ADMA, eNOS concentration and left ventricular structure and function in CKD patients and to assess the impact of the type of dialyzer on serum ADMA and eNOS concentrations after a haemodialysis (HD) session. MATERIAL AND METHODS: Peripheral bloo...
Source: Current Vascular Pharmacology - January 12, 2016 Category: Drugs & Pharmacology Authors: Bartnicki P, Kowalczyk M, Franczyk-Skóra B, Baj Z, Rysz J Tags: Curr Vasc Pharmacol Source Type: research

Imiquimod Increases Cutaneous VEGF Expression in Imiquimod-induced Psoriatic Mouse Model.
Abstract Psoriasis is a chronic skin disease of unknown aetiology but increasing evidence suggests that cutaneous angiogenesis plays an important role. Vascular endothelial growth factor (VEGF) is one of the pro-angiogenic cytokines which is related to the pathogenesis of psoriasis. Our study evaluated the influence of imiquimod (IMQ) on VEGF in IMQ-induced mouse model. Balb/c female mice (n=16) 8-12 weeks of age were randomly divided into an experimental group (5% IMQ cream) and the control group (Vaseline cream). Serum levels of circulating VEGF-A were quantified by enzyme-linked immunosorbent assay. VEGF protei...
Source: Current Vascular Pharmacology - January 6, 2016 Category: Drugs & Pharmacology Authors: Wu HH, Xie WL, Zhao YK, Liu JH, Luo DQ Tags: Curr Vasc Pharmacol Source Type: research

Lipid-lowering therapy in HIV-infected patients: relationship with antiretroviral agents and impact of substance-related disorders.
Abstract BACKGROUND The use of combination antiretroviral therapy (cART) has significantly decreased the morbidity and mortality associated with human immunodeficiency virus (HIV) infection. Lipid disorders, including lipodystrophy, hypertriglyceridemia, and hypercholesterolemia, remain the most commonly reported metabolic disorders among those treated with long-term cART. Mounting evidence suggests an association between drug abuse and poor glycemic control and diabetes complications. Substance related disorders (SRD) may increase the risk of metabolic syndrome. MATERIALS AND METHODS The aim of this retrospective...
Source: Current Vascular Pharmacology - January 6, 2016 Category: Drugs & Pharmacology Authors: Bednasz C, Luque AE, Zingman BS, Fischl MA, Gripshover BM, Venuto CS, Gu J, Feng Z, DiFrancesco R, Morse GD, Ma Q Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Bivalirudin and the Matrix Trial: The End of the Story?
PMID: 26642872 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 12, 2015 Category: Drugs & Pharmacology Authors: De Luca G, Suryapranata H Tags: Curr Vasc Pharmacol Source Type: research

Editorial (Thematic Issue: Pharmacologic Strategies with Afterload Reduction in Low Cardiac Output Syndrome After Pediatric Cardiac Surgery).
PMID: 26642871 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 12, 2015 Category: Drugs & Pharmacology Authors: Bautista-Hernandez V, Almodovar MC Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
PMID: 26642873 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 12, 2015 Category: Drugs & Pharmacology Authors: Katsiki N, Christou GA, Kiortsis DN Tags: Curr Vasc Pharmacol Source Type: research

Adiponectin: an Endothelium-Derived Vasoprotective Factor?
Abstract Adipose tissue (AT) is now widely accepted as a key secretary organ, as well as an energy storage depot. It secretes a series of cytokines, hormones and bioactive molecules: adipokines. Adiponectin is an abundant systemic adipokine that uniquely is reduced in obesity and increases on weight loss, is anti-inflammatory, promotes insulin sensitivity and affords cardiometabolic protection. It was considered a true adipokine, in that it is exclusively generated by the adipocytes of the adipose tissue. However, recent evidence points to it being secreted by a range of other organs. This review summarizes the no...
Source: Current Vascular Pharmacology - December 2, 2015 Category: Drugs & Pharmacology Authors: Shen L, Evans IM, Souza DS, Dreifaldt M, Dashwood MR, Mohamed-Ali V Tags: Curr Vasc Pharmacol Source Type: research

Vascular Endothelium and Hypovolemic Shock.
Abstract Endothelium is a site of metabolic activity and has a major reservoir of multipotent stem cells. It plays a vital role in the vascular physiological, pathophysiological and reparative processes. Endothelial functions are significantly altered following hypovolemic shock due to ischemia of the endothelial cells and by reperfusion due to resuscitation with fluids. Activation of endothelial cells leads to release of vasoactive substances (nitric oxide, endothelin, platelet activating factor, prostacyclin, mitochondrial N-formyl peptide), mediators of inflammation (tumor necrosis factor α, interleukins,...
Source: Current Vascular Pharmacology - December 2, 2015 Category: Drugs & Pharmacology Authors: Gulati A Tags: Curr Vasc Pharmacol Source Type: research

Is Erectile Dysfunction an Example of Abnormal Endothelial Function?
Abstract Erectile dysfunction (ED) affects approximately half of men during middle age. Erectile dysfunction is often an early symptom of systemic vascular disease, which may precipitate significant cardiac events. The pathophysiology of ED and cardiovascular disease are closely linked. Endothelial dysfunction occurs at an early stage in ED and cardiovascular disease (CVD). In normal conditions, nitric oxide dependent and independent mechanisms regulate penile vascular tone ensuring an appropriate balance of vasoconstriction and vasodilatation. A normal endothelium is responsible for mediating the effect of pro-er...
Source: Current Vascular Pharmacology - December 2, 2015 Category: Drugs & Pharmacology Authors: Blick C, Ritchie RW, Sullivan ME Tags: Curr Vasc Pharmacol Source Type: research

The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes.
Abstract Diabetes mellitus is a major risk factor for the development of cardiovascular disease due to increased vascular inflammatory and oxidative stress favouring atherogenesis. Endothelial dysfunction has received increasing attention as a potential contributor to the pathogenesis of vascular disease in diabetes mellitus. Although the underlying cause of endothelial dysfunction is multifactorial, a key factor is impairment of the bioavailability of nitric oxide (NO). Emerging evidence suggest that upregulation of arginase is of central importance for reduced NO bioavailability due to competition for the substr...
Source: Current Vascular Pharmacology - December 2, 2015 Category: Drugs & Pharmacology Authors: Pernow J, Jung C Tags: Curr Vasc Pharmacol Source Type: research

Valve Endothelial Cells - Not Just Any Old Endothelial Cells.
Abstract Heart valves are sophisticated cellularised structures that perform a complex series of dynamic functions during each cardiac cycle. The endothelial cells (ECs) that cover both surfaces of the valve, play an important role in ensuring that the valve functions are in an optimal manner. They are also postulated to protect the valve against calcific disease. These functions include a role in embryonic development, regulation of cellular attachment, modulation of the mechanical properties of the valve, prevention of valve interstitial cell differentiation into pathological cell phenotypes and regulation of th...
Source: Current Vascular Pharmacology - December 2, 2015 Category: Drugs & Pharmacology Authors: Mongkoldhumrongkul N, Yacoub MH, Chester AH Tags: Curr Vasc Pharmacol Source Type: research

Regulation of Vascular Endothelium Inflammatory Signalling by Shear Stress.
Abstract The vascular endothelium plays a pivotal role in regulating vascular homeostasis. Blood flow exerts several mechanical forces on the luminal surface of the endothelial cell (EC) including pressure, circumferential stretch, and shear stress. It is widely believed that shear stress plays a central role in regulating EC inflammatory responses and the pathogenesis of atherosclerosis. High shear stress can induce an antiinflammatory status in EC, which is partially mediated by the production of proteins and transcription factors able to suppress different proinflammatory signalling pathways. In this review, we...
Source: Current Vascular Pharmacology - December 2, 2015 Category: Drugs & Pharmacology Authors: Zakkar M, Angelini GD, Emanueli C Tags: Curr Vasc Pharmacol Source Type: research

Purinergic Signalling and Endothelium.
Abstract Purinergic signalling is involved in the control of vascular tone and remodelling. Endothelial cells release purines and pyrimidines in response to changes in blood flow (evoking shear stress) and hypoxia. They then act on P2Y, P2X and P1 receptors on endothelial cells leading to release of EDRF mediated by nitric oxide and prostaglandins and EDHF, resulting in vasodilatation. The therapeutic potential of purinergic compounds for the treatment of vascular diseases, including hypertension, ischaemia, atherosclerosis, migraine and coronary artery and diabetic vascular disease as well as vasospasm is discuss...
Source: Current Vascular Pharmacology - December 2, 2015 Category: Drugs & Pharmacology Authors: Burnstock G Tags: Curr Vasc Pharmacol Source Type: research

Endothelial Lessons.
Abstract This essay focuses on nine important lessons learned during more than thirty years of endothelial research. They include: the danger of hiding behind a word, the confusion generated by abbreviations, the need to define the physiological role of the response studied, the local role of endothelium-dependent responses, the strength of pharmacological analyses, endothelial dysfunction as consequence and cause of disease, the importance of rigorous protocols, the primacy of in vivo studies and the importance of serendipity. PMID: 26638800 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 2, 2015 Category: Drugs & Pharmacology Authors: Vanhoutte PM Tags: Curr Vasc Pharmacol Source Type: research

Impact of Polypharmacy on Adherence to Evidence-Based Medication in Patients who Underwent Percutaneous Coronary Intervention.
CONCLUSION: In patients who underwent PCI, polypharmacy at discharge could play a negative role in the adherence to the first refill of EBM. Further studies should investigate other parameters that contribute to long term non-adherence. PMID: 26517700 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 29, 2015 Category: Drugs & Pharmacology Authors: Mohammed S, Arabi A, El-Menyar A, Abdulkarim S, AlJundi A, Alqahtani A, Arafa S, Al Suwaidi J Tags: Curr Vasc Pharmacol Source Type: research

Venous Thromboembolism Risk and Adequacy of Prophylaxis in High Risk Pregnancy in the Arabian Gulf.
CONCLUSION: A large proportion of pregnant women in the Arabian Gulf countries have ≥ 1 VTE risk factor with even a smaller fraction on prophylaxis. VTE risk assessment must be adopted to identify those at risk who would need VTE prophylaxis. PMID: 26517701 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 29, 2015 Category: Drugs & Pharmacology Authors: Alsayegh F, Al-Jassar W, Wani S, Tahlak M, Albahar A, Al Kharusi L, Al-Tamimi H, El-Taher F, Mahmood N, Al-Zakwani I Tags: Curr Vasc Pharmacol Source Type: research

Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf.
li K, Al-Hashmi K, Al-Rasadi K Abstract We evaluated the control of cardiovascular disease (CVD) risk factors among patients with atherosclerotic cardiovascular disease (ASCVD) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolaemia (CEPHEUS) in the Arabian Gulf. Of the 4398 enrolled patients, overall mean age was 57 ± 11 years, 60% were males, 13% were smokers, 76% had diabetes, 71% had metabolic syndrome and 78% had very high ASCVD risk status. The proportion of subjects with body mass index
Source: Current Vascular Pharmacology - October 26, 2015 Category: Drugs & Pharmacology Authors: Al-Zakwani I, Al Mahmeed W, Arafah M, Al-Hinai AT, Shehab A, Al Tamimi O, Al Awadhi M, Al Herz S, Al Anazi F, Al Nemer K, Metwally O, Alkhadra A, Fakhry M, Elghetany H, Medani AR, Yusufali AH, Al Jassim O, Al Hallaq O, Baslaib FO, Amin H, Santos RD, Al-Wa Tags: Curr Vasc Pharmacol Source Type: research

Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not AII.
PMID: 26459809 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 16, 2015 Category: Drugs & Pharmacology Authors: Athyros VG, Tziomalos K, Karagiannis A Tags: Curr Vasc Pharmacol Source Type: research

A hypothesis for the role of RECK in angiogenesis.
via L Abstract Angiogenesis is a key process by which new capillary blood vessels are formed, sustaining the supply of oxygen and other nutrients to the body allowing its growth and wound healing, among others. However, angiogenesis also associates with pathological processes, such us tumor growth. Vascular endothelial cells produce different matrix remodeling enzymes such as matrix metalloproteinases and a disintegrin and metalloproteinases, which have both positive and negative effects on angiogenesis, regulating the cell environment and signaling. However, little is known about the regulation of the activity of...
Source: Current Vascular Pharmacology - October 14, 2015 Category: Drugs & Pharmacology Authors: Gutiérrez J, Droppelmann CA, Salsoso R, Westermeier F, Toledo F, Salomon C, Sanhueza C, Pardo F, Leiva A, Sobrevia L Tags: Curr Vasc Pharmacol Source Type: research

Pharmacological manipulation of peripheral vascular resistance in special clinical situations after pediatric cardiac surgery.
This article addresses the eighth of eight topics comprising the special issue entitled "Pharmacologic strategies with afterload reduction in low cardiac output syndrome after pediatric cardiac surgery". PMID: 26463983 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 14, 2015 Category: Drugs & Pharmacology Authors: Moga MA, Nguyen N, Mazwi ML, Costello JM Tags: Curr Vasc Pharmacol Source Type: research

Pharmacological Manipulation of Peripheral Vascular Resistance in Single Ventricle Patients (Stages I, II, and III of Palliation).
This article addresses the seventh of eight topics comprising the special issue entitled "Pharmacologic strategies with afterload reduction in low cardiac output syndrome after pediatric cardiac surgery". PMID: 26463984 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 14, 2015 Category: Drugs & Pharmacology Authors: Schwartz SM, Floh AA, Laussen PC Tags: Curr Vasc Pharmacol Source Type: research

Inodilators in the management of low cardiac output syndrome after pediatric cardiac surgery.
This article addresses the sixth of eight topics comprising the special issue entitled "Pharmacologic strategies with afterload reduction in low cardiac output syndrome after pediatric cardiac surgery". PMID: 26463985 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 14, 2015 Category: Drugs & Pharmacology Authors: Ferrer-Barba A, Gonzalez-Rivera I, Bautista-Hernandez V Tags: Curr Vasc Pharmacol Source Type: research

Pulmonary Vasodilators in the Management of Low Cardiac Output Syndrome after Pediatric Cardiac Surgery.
This article addresses the fifth of eight topics comprising the special issue entitled "Pharmacologic strategies with afterload reduction in low cardiac output syndrome after pediatric cardiac surgery". PMID: 26463986 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 14, 2015 Category: Drugs & Pharmacology Authors: Avila-Alvarez A, Del Cerro Marin MJ, Bautista-Hernandez V Tags: Curr Vasc Pharmacol Source Type: research

A review of systemic vasodilators in low cardiac output syndrome following pediatric cardiac surgery.
This article addresses the fourth of eight topics comprising the special issue entitled "Pharmacologic strategies with afterload reduction in low cardiac output syndrome after pediatric cardiac surgery". PMID: 26463987 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 14, 2015 Category: Drugs & Pharmacology Authors: Mills KI, Costello JM, Almodovar MC Tags: Curr Vasc Pharmacol Source Type: research

Theoretical and evidence-based benefit of afterload reduction in the postoperative pediatric heart.
This article addresses the third of eight topics comprising the special issue entitled "Pharmacologic strategies with afterload reduction in low cardiac output syndrome after pediatric cardiac surgery". PMID: 26463988 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 14, 2015 Category: Drugs & Pharmacology Authors: DiNardo JA, Almodovar MC Tags: Curr Vasc Pharmacol Source Type: research

Pathophysiology of Post-Operative Low Cardiac Output Syndrome.
This article addresses the second of eight topics comprising the special issue entitled "Pharmacologic strategies with afterload reduction in low cardiac output syndrome after pediatric cardiac surgery". PMID: 26463989 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 14, 2015 Category: Drugs & Pharmacology Authors: Epting CL, McBride ME, Wald EL, Costello JM Tags: Curr Vasc Pharmacol Source Type: research